Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 305, Issue 11, 2013, Pages

  Kalish, Brian T ^a   Le, Hau D ^a,b   Fitzgerald, Jonathan M ^c   Wang, Samantha ^d   Seamon, Kyle ^d   Gura, Kathleen M ^a   Gronert, Karsten ^d   Puder, Mark ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lipid mediators; Liver disease; Omega 3; Omega 6; Parenteral nutrition

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FISH OIL BASED LIPID EMULSION; HDROXYEICOSATETRIENOIC ACID; HYDROXYDOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE B4; LIPID EMULSION; LIPIDOME; LIPOXIN; MARESIN 1; MEDIATOR COMPLEX; OMEGA 3 FATTY ACID; PROTECTIN D1; SOYBEAN OIL BASED LIPID EMULSION; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMAN; IN VIVO STUDY; LIPIDOMICS; LIVER; LIVER DISEASE; LIVER FAILURE; LIVER PROTECTION; MALE; METABOLOME; MOUSE; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; VALIDATION STUDY;

LIPID MEDIATORS; LIVER DISEASE; OMEGA-3; OMEGA-6; PARENTERAL NUTRITION;

ADMINISTRATION, ORAL; ANIMALS; EMULSIONS; FATTY ACIDS, OMEGA-3; FATTY LIVER; FEMALE; HUMANS; INFANT; INFLAMMATION MEDIATORS; INJECTIONS, INTRAVENOUS; MALE; MICE; SOYBEAN OIL;

EID: 84889046151     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00106.2013     Document Type: Article

References (41)

1. Alwayn IP, Gura K, Nosé V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. ω-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 57: 445-452, 2005
2. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52: 1364-1370, 2003
3. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S, Wechsler ME, Israel E, Levy BD. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 5: 174ra26, 2013
4. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. ω-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 187: 1957-1969, 2011
5. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 28: N27-N36, 2000
6. Buxton DB, Fisher RA, Robertson SM, Olson MS. Stimulation of glycogenolysis and vasoconstriction by adenosine and adenosine analogues in the perfused rat liver. Biochem J 248: 35-41, 1987
7. Chiang N, Fredman G, Bäckhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528, 2012
8. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition 14: 158-164, 1998
9. Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177: 5902-5911, 2006
10. Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, Brenner DA, Schemmer P, Bradford BU, Rivera CA, Zhong Z, Thurman RG. Kupffer cell-derived prostaglandin E2 is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 279: G100-G106, 2000
11. González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán- Salvador E, Titos E, Martínez-Clemente M, López-Parra M, Arroyo V, Clària J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J 23: 1946-1957, 2009
12. González-Périz A, Planagumà A, Gronert K, Miquel R, López-Parra M, Titos E, Horrillo R, Ferré N, Deulofeu R, Arroyo V, Rodés J, Clària J. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 20: 2537-2539, 2006
13. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 9: 873-879, 2008
14. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous _-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103: 11276-11281, 2006
15. Katagiri H, Ito Y, Ishii KI, Hayashi I, Suematsu M, Yamashina S, Murata T, Narumiya S, Kakita A, Majima M. Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice. Hepatology 39: 139-150, 2004
16. Lima-Garcia JF, Dutra RC, da Silva K, Motta EM, Campos MM, Calixto JB. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol 164: 278-293, 2011
17. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58: 1476-1484, 2012
18. Meisel JA, Le HD, de Meijer VE, Nosé V, Gura KM, Mulkern RV, Akhavan Sharif MR, Puder M. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg 46: 666-673, 2011
19. Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez- Clemente M, González-Périz A, López-Vicario C, Barak Y, Arroyo V, Clària J. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 25: 2538-2550, 2011
20. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 142: 367-373, 1993
21. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. The human serum metabolome. PLos One 6: e16957, 2011
22. Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 250: 395-402, 2009
23. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol 189: 1036-1042, 2012
24. Rangel SJ, Calkins CM, Cowles RA, Barnhart DC, Huang EY, Abdullah F, Arca MJ, Teitelbaum DH, 2011 American Pediatric Surgical Association Outcomes and Clinical Trials Committee. Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg 47: 225-240, 2012
25. Raszeja-Wyszomirska J, Safranow K, Milkiewicz M, Milkiewicz P, Szynkowska A, Stachowska E. Lipidic last breath of life in patients with alcoholic liver disease. Prostaglandins Other Lipid Mediat 99: 51-56, 2012
26. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171-1176, 1987
27. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM, Dennison RJ, Connor KM, Aderman CM, Liclican E, Carughi A, Perelman D, Kanaoka Y, Sangiovanni JP, Gronert K, Smith LE. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids. Sci Transl Med 3: 69ra12, 2011
28. Schacky von C, Kiefl R, Marcus AJ, Broekman MJ, Kaminski WE. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim Biophys Acta 1166: 20-24, 1993
29. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26: 1755-1765, 2012
30. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of ω-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196: 1025-1037, 2002
31. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 111: 5922-5943, 2011
32. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206: 15-23, 2009
33. Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost 7 Suppl 1: 44-48, 2009
34. Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 27: 131-137, 1998
35. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamäki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Järvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 286: E941-E949, 2004
36. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metab Clin Exp 56: 1418-1424, 2007
37. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169-2176, 2004
38. von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, van Rooijen N, Brown CR, Krantz BA, Leppla SH, Gronert K, Vance RE. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490: 107-111, 2012
39. Wales PW, de Silva N, Kim JH, Lecce L, Sandhu A, Moore AM. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg 40: 755-762, 2005
40. Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol Chapt 14: Unit 14.26, 2011
41. Yokoyama Y, Nimura Y, Nagino M, Bland KI, Chaudry IH. Role of thromboxane in producing hepatic injury during hepatic stress. Arch Surg 140: 801-807, 2005.